IBEX develops AI-powered diagnostic solutions that enhance the accuracy and efficiency of cancer detection by analyzing tissue samples with deep learning algorithms trained on over 10 million pathology slides. This technology provides pathologists with reliable insights, improving diagnostic confidence and patient outcomes in cancer care.
Funding
$122.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Pathologists face increasing workloads and complexity in cancer diagnostics, requiring them to analyze a growing number of tissue samples with high accuracy. Manual analysis can be time-consuming and prone to variability, potentially leading to delayed or inaccurate diagnoses.
Solution
Ibex develops AI-powered diagnostic solutions that assist pathologists in the detection of cancer by analyzing digital pathology slides. Using deep learning algorithms trained on a large dataset of pathology slides, the platform identifies suspicious areas and provides insights to pathologists, enhancing diagnostic accuracy and efficiency. The AI algorithms can detect cancer and other diagnostic features in various tissue types, acting as a second reviewer to improve the quality and speed of diagnosis. By integrating AI into the diagnostic workflow, Ibex aims to improve patient outcomes through faster and more accurate cancer detection.
Target Audience
The primary target audience includes pathologists, physicians, and healthcare systems seeking to improve the accuracy and efficiency of cancer diagnosis.
Features
- AI-powered detection of cancer and other diagnostic features in multiple tissue types
- Deep learning algorithms trained on over 10 million pathology slides
- Clinically proven accuracy, enhanced efficiency, and improved user experience for pathologists
- Identification of small foci of cancer and higher-grade cancers that may be missed by manual review
- Algorithms for Gleason grading, tumor sizing, and detection of perineural invasion in prostate cancer
- Platform of choice for leading physicians, health systems, and diagnostic solution providers